See more : Air Lease Corporation (AL-PA) Income Statement Analysis – Financial Results
Complete financial analysis of BrainsWay Ltd. (BWAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BrainsWay Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Ford Motor Company 6.500% Notes (F-PD) Income Statement Analysis – Financial Results
- Henan Thinker Automatic Equipment Co., Ltd. (603508.SS) Income Statement Analysis – Financial Results
- China Index Holdings Limited (CIH) Income Statement Analysis – Financial Results
- Grand Industrial Holding Co., Ltd. (000626.SZ) Income Statement Analysis – Financial Results
- Veeva Systems Inc. (VEEV) Income Statement Analysis – Financial Results
BrainsWay Ltd. (BWAY)
About BrainsWay Ltd.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 31.79M | 27.18M | 29.66M | 22.06M | 23.10M | 16.40M | 11.15M | 11.52M | 6.80M | 3.38M | 1.19M | 364.25K |
Cost of Revenue | 8.31M | 7.13M | 6.60M | 5.06M | 5.13M | 3.59M | 2.60M | 2.43M | 1.47M | 656.00K | 199.00K | 46.07K |
Gross Profit | 23.48M | 20.05M | 23.06M | 17.00M | 17.97M | 12.81M | 8.55M | 9.10M | 5.33M | 2.72M | 990.00K | 318.18K |
Gross Profit Ratio | 73.86% | 73.77% | 77.75% | 77.07% | 77.80% | 78.11% | 76.72% | 78.94% | 78.44% | 80.59% | 83.26% | 87.35% |
Research & Development | 6.53M | 7.68M | 6.39M | 5.82M | 7.88M | 6.16M | 5.34M | 3.79M | 4.10M | 6.44M | 3.69M | 5.97M |
General & Administrative | 5.32M | 6.85M | 5.78M | 4.72M | 4.39M | 8.23M | 7.47M | 5.74M | 3.61M | 2.34M | 1.43M | 1.31M |
Selling & Marketing | 16.46M | 18.20M | 15.88M | 11.28M | 13.27M | 3.11M | 1.83M | 1.21M | 1.93M | 1.21M | 633.00K | 140.34K |
SG&A | 21.64M | 25.05M | 21.66M | 16.01M | 17.66M | 11.34M | 9.30M | 6.95M | 5.54M | 3.55M | 2.06M | 1.45M |
Other Expenses | -9.79M | 0.00 | 0.00 | 0.00 | 916.00K | 427.00K | 523.00K | 426.00K | 200.00K | 11.00K | -504.00K | 0.00 |
Operating Expenses | 28.02M | 32.73M | 28.06M | 21.83M | 26.45M | 17.92M | 15.16M | 11.17M | 9.84M | 10.00M | 5.26M | 5.95M |
Cost & Expenses | 36.71M | 39.86M | 34.66M | 26.89M | 31.58M | 21.51M | 17.76M | 13.59M | 11.31M | 10.66M | 5.46M | 5.99M |
Interest Income | 2.17M | 1.11M | 225.00K | 61.00K | 175.00K | 44.00K | 22.00K | 12.00K | 18.00K | 93.00K | 304.00K | 288.19K |
Interest Expense | 48.00K | 46.00K | 1.42M | 319.00K | 398.00K | 354.00K | 360.00K | 404.00K | 98.00K | 525.00K | 283.00K | 0.00 |
Depreciation & Amortization | 1.34M | 1.54M | 1.69M | 1.62M | 2.80M | 1.23M | 1.07M | 649.00K | 611.00K | 336.00K | 206.00K | 109.28K |
EBITDA | -2.31M | -11.45M | -4.59M | -3.42M | -8.48M | -4.65M | -5.68M | -1.42M | -3.44M | -6.21M | -4.06M | -5.62M |
EBITDA Ratio | -7.27% | -41.02% | -11.17% | -21.89% | -28.50% | -26.85% | -49.92% | -12.75% | -57.54% | -203.22% | -79.98% | -1,530.22% |
Operating Income | -4.93M | -12.68M | -5.00M | -4.83M | -8.48M | -5.11M | -6.61M | -2.07M | -4.51M | -7.28M | -4.27M | -5.68M |
Operating Income Ratio | -15.50% | -46.67% | -16.86% | -21.89% | -36.69% | -31.19% | -59.32% | -17.95% | -66.25% | -215.30% | -358.87% | -1,560.22% |
Total Other Income/Expenses | 981.00K | -351.00K | -1.42M | -319.00K | -1.43M | -1.16M | -274.00K | -328.00K | 418.00K | 732.00K | -2.83M | -233.28K |
Income Before Tax | -3.95M | -13.03M | -6.42M | -5.15M | -9.91M | -6.27M | -6.89M | -2.40M | -4.09M | -6.55M | -7.09M | -5.92M |
Income Before Tax Ratio | -12.41% | -47.96% | -21.64% | -23.34% | -42.88% | -38.24% | -61.78% | -20.80% | -60.10% | -193.64% | -596.64% | -1,624.27% |
Income Tax Expense | 251.00K | 315.00K | 43.00K | 237.00K | 422.00K | 209.00K | 169.00K | 404.00K | 98.00K | 525.00K | 28.00K | 0.00 |
Net Income | -4.20M | -13.35M | -6.46M | -5.39M | -10.33M | -6.48M | -7.05M | -2.40M | -4.09M | -6.55M | -7.12M | -5.92M |
Net Income Ratio | -13.20% | -49.12% | -21.79% | -24.41% | -44.71% | -39.51% | -63.29% | -20.80% | -60.10% | -193.64% | -598.99% | -1,624.27% |
EPS | -0.25 | -0.87 | -0.41 | -0.48 | -1.01 | -0.78 | -0.96 | -0.33 | -0.57 | -0.92 | -1.11 | -0.49 |
EPS Diluted | -0.25 | -0.87 | -0.41 | -0.48 | -1.01 | -0.78 | -0.96 | -0.33 | -0.57 | -0.92 | -1.11 | -0.49 |
Weighted Avg Shares Out | 16.58M | 15.39M | 15.58M | 11.22M | 10.25M | 8.32M | 7.38M | 7.25M | 7.23M | 7.08M | 6.43M | 12.17M |
Weighted Avg Shares Out (Dil) | 16.58M | 15.39M | 15.58M | 11.22M | 10.25M | 8.32M | 7.38M | 7.25M | 7.23M | 7.13M | 6.43M | 12.17M |
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
Brainsway (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
Wall Street Analysts Believe Brainsway (BWAY) Could Rally 32.01%: Here's is How to Trade
Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?
Here's Why Momentum in Brainsway (BWAY) Should Keep going
Are Medical Stocks Lagging Brainsway (BWAY) This Year?
Source: https://incomestatements.info
Category: Stock Reports